Lift Biosciences LtdLIfT BioSciences Ltd, active in London, Galway and Houston, has been awarded a grant of €12m from the Disruptive Technologies Innovation Fund (DTIF) to support the clinical translation of its Immuno-Modulatory Alpha Neutrophils (IMANs). This funding will enable the preparation of the world’s first allogeneic therapy using synthetically programmed neutrophil granulocytes for Phase I trials.
Tag Archive for: Phase I
CDC/Phil_ImagesLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline programme.
Roche, Herzog&De MeuronObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.